Interacting with thioredoxin-1-disease or no disease?

Antioxidants and Redox Signaling

Volumn 18, Issue 9, 2013, Pages 1053-1062

  Zschauer, Tim Christian ^a   Matsushima, Shouji ^b   Altschmied, Joachim ^a   Shao, Dan ^b   Sadoshima, Junichi ^b   Haendeler, Judith ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; THIOREDOXIN 1;

ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL NUCLEUS; CELL STRESS; CELL SURVIVAL; CYTOSOL; DETOXIFICATION; DIABETES MELLITUS; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; REVIEW;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CARDIOVASCULAR SYSTEM; CYSTEINE; CYSTINE; DIABETES MELLITUS, TYPE 2; HEART DISEASES; HUMANS; HYDROGEN PEROXIDE; MICE; MODELS, CARDIOVASCULAR; MOLECULAR TARGETED THERAPY; MYOCARDIUM; NADP; NEOPLASM PROTEINS; NEOPLASMS; OXIDATION-REDUCTION; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84874066403     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4822     Document Type: Review

References (64)

1. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, and Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133: 978-993, 2008.
2. Ago T, Yeh I, Yamamoto M, Schinke-Braun M, Brown JA, Tian B, and Sadoshima J. Thioredoxin1 upregulates mito-chondrial proteins related to oxidative phosphorylation and TCA cycle in the heart. Antioxid Redox Signal 8: 1635-1650, 2006.
3. Billiet L, Furman C, Larigauderie G, Copin C, Page S, Fru-chart JC, Brand K, and Rouis M. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J Cell Physiol 214: 183-191, 2008.
4. Busse R and Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 33: 181-194, 1996.
5. Chen B, Guan D, Cui ZJ, Wang X, and Shen X. Thioredoxin 1 downregulates MCP-1 secretion and expression in human endothelial cells by suppressing nuclear translocation of activator protein 1 and redox factor-1. Am J Physiol Cell Physiol 298: C1170-C1179, 2010.
6. Clarke M, Bennett M, and Littlewood T. Cell death in the cardiovascular system. Heart 93: 659-664, 2007.
7. Dai YS, Xu J, and Molkentin JD. The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol 25: 9936-9948, 2005.
8. Davis FJ, Gupta M, Camoretti-Mercado B, Schwartz RJ, and Gupta MP. Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4. Implications in cardiac muscle gene regulation during hypertrophy. J Biol Chem 278: 20047-20058, 2003.
9. Day AM, Brown JD, Taylor SR, Rand JD, Morgan BA, and Veal EA. Inactivation of a peroxiredoxin by hydrogen peroxide is critical for thioredoxin-mediated repair of oxidized proteins and cell survival. Mol Cell 45: 398-408, 2012.
10. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, and Vlassara H. Prevention conference VI: diabetes and cardiovascular disease: writing group II: pathogenesis of atherosclerosis in diabetes. Circulation 105: e138-e143, 2002.
11. Fu C, Wu C, Liu T, Ago T, Zhai P, Sadoshima J, and Li H. Elucidation of thioredoxin target protein networks in mouse. Mol Cell Proteomics 8: 1674-1687, 2009.
12. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM, and Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cys-teine 69. Nat Cell Biol 4: 743-749, 2002.
13. 2 stimulate degradation of thioredoxin-1: implication for endothelial cell apoptosis. J Biol Chem 280: 42945-42951, 2005.
14. Haendeler J, Tischler V, Hoffmann J, Zeiher AM, and Dim-meler S. Low doses of reactive oxygen species protect en-dothelial cells from apoptosis by increasing thioredoxin-1 expression. FEBS Lett 577: 427-433, 2004.
15. Han A, He J, Wu Y, Liu JO, and Chen L. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J Mol Biol 345: 91-102, 2005.
16. Hansen JM, Watson WH, and Jones DP. Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxicol Sci 82: 308-317, 2004.
17. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94: 3633-3638, 1997.
18. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
19. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Na-kayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M, and Hori M. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105: 509-515, 2002.
20. Hoffmann J, Dimmeler S, and Haendeler J. Shear stress increases the amount of S-nitrosylated molecules in endothe-lial cells: important role for signal transduction. FEBS Lett 551: 153-158, 2003.
21. Holmgren A. Thioredoxin. 6. The amino acid sequence of the protein from Escherichia coli B. Eur J Biochem 6: 475-484, 1968.
22. Holmgren A. Antioxidant function of thioredoxin and glu-taredoxin systems. Antioxid Redox Signal 2: 811-820, 2000.
23. Holmgren A, Soderberg BO, Eklund H, and Branden CI. Three-dimensional structure of Escherichia coli thioredoxin-S2 to 2.8 A resolution. Proc Natl Acad Sci USA 72: 2305-2309, 1975.
24. Imen JS, Billiet L, Cuaz-Perolin C, Michaud N, and Rouis M. The regulated in development and DNA damage response 2 (REDD2) gene mediates human monocyte cell death through a reduction in thioredoxin-1 expression. Free Radic Biol Med 46: 1404-1410, 2009.
25. Izumiya Y, Kim S, Izumi Y, Yoshida K, Yoshiyama M, Matsuzawa A, Ichijo H, and Iwao H. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 93: 874-883, 2003.
26. Kuster GM, Pimentel DR, Adachi T, Ido Y, Brenner DA, Cohen RA, Liao R, Siwik DA, and Colucci WS. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 111: 1192-1198, 2005.
27. Laurent TC, Moore EC, and Reichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem 239: 3436-3444, 1964.
28. Leal J, Luengo-Fernandez R, Gray A, Petersen S, and Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27: 1610-1619, 2006.
29. Liu Y and Min W. Thioredoxin promotes ASK1 ubiquitina-tion and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90: 1259-1266, 2002.
30. Lukosz M, Jakob S, Buchner N, Zschauer TC, Altschmied J, and Haendeler J. Nuclear redox signaling. Antioxid Redox Signal 12: 713-742, 2010.
31. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178: 179-185, 1996.
32. Miranda-Vizuete A, Ljung J, Damdimopoulos AE, Gus-tafsson JA, Oko R, Pelto-Huikko M, and Spyrou G. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J Biol Chem 276: 31567-31574, 2001.
33. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
34. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hypergly-caemic damage. Nature 404: 787-790, 2000.
35. Oka S, Ago T, Kitazono T, Zablocki D, and Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med (Berl) 87: 785-791, 2009.
36. Pimentel DR, Adachi T, Ido Y, Heibeck T, Jiang B, Lee Y, Melendez JA, Cohen RA, and Colucci WS. Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation. J Mol Cell Cardiol 41: 613-622, 2006.
37. Powis G and Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7: 392-397, 2007.
38. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tuder RM, and Biswal S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114: 1248-1259, 2004.
39. Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
40. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
41. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
42. Samuel SM, Thirunavukkarasu M, Penumathsa SV, Koneru S, Zhan L, Maulik G, Sudhakaran PR, and Maulik N. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 121: 1244-1255, 2010.
43. Schenk H, Klein M, Erdbrugger W, Droge W, and Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci USA 91: 1672-1676, 1994.
44. Schroeder P, Popp R, Wiegand B, Altschmied J, and Haen-deler J. Nuclear redox-signaling is essential for apoptosis inhibition in endothelial cells-important role for nuclear thioredoxin-1. Arterioscler Thromb Vasc Biol 27: 2325-2331, 2007.
45. Schulze PC, De Keulenaer GW, Yoshioka J, Kassik KA, and Lee RT. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res 91: 689-695, 2002.
46. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, and Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279: 30369-30374.
47. Spyrou G, Enmark E, Miranda-Vizuete A, and Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 272: 2936-2941, 1997.
48. Sugden PH and Clerk A. Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myo-cytes. Antioxid Redox Signal 8: 2111-2124, 2006.
49. Tang K, Li X, Zheng MQ, and Rozanski GJ. Role of apoptosis signal-regulating kinase-1-c-Jun NH2-terminal kinase-p38 signaling in voltage-gated K+ channel remodeling of the failing heart: regulation by thioredoxin. Antioxid Redox Signal 14: 25-35, 2011.
50. Tao L, Gao E, Bryan NS, Qu Y, Liu HR, Hu A, Christopher TA, Lopez BL, Yodoi J, Koch WJ, Feelisch M, and Ma XL. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci USA 101: 11471-11476, 2004.
51. Tao L, Jiao X, Gao E, Lau WB, Yuan Y, Lopez B, Christopher T, Ramachandra Rao SP, Williams W, Southan G, Sharma K, Koch W, and Ma XL. Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis. Circulation 114: 1395-1402, 2006.
52. Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, and Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 101: 2450-2453, 2000.
53. Turoczi T, Chang VW, Engelman RM, Maulik N, Ho YS, and Das DK. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 35: 695-704, 2003.
54. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 18 Suppl E: E19-E29, 1997.
55. Wang XL, Lau WB, Yuan YX, Wang YJ, Yi W, Christopher TA, Lopez BL, Liu HR, and Ma XL. Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity. Am J Physiol Endocrinol Metab 299: E207-E214, 2010.
56. World C, Spindel ON, and Berk BC. Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-alpha: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol 31: 1890-1897, 2011.
57. Xu D, Rovira II, and Finkel T. Oxidants painting the cysteine chapel: redox regulation of PTPs. Dev Cell 2: 251-252, 2002.
58. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, and Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112: 1395-1406, 2003.
59. Yamanaka H, Maehira F, Oshiro M, Asato T, Yanagawa Y, Takei H, and Nakashima Y. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 271: 796-800, 2000.
60. Yamawaki H, Pan S, Lee RT, and Berk BC. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest 115: 733-738, 2005.
61. Yin T, Hou R, Liu S, Lau WB, Wang H, and Tao L. Nitrative inactivation of thioredoxin-1 increases vulnerability of diabetic hearts to ischemia/reperfusion injury. J Mol Cell Cardiol 49: 354-361, 2010.
62. Yoshioka J, Imahashi K, Gabel SA, Chutkow WA, Burds AA, Gannon J, Schulze PC, MacGillivray C, London RE, Murphy E, and Lee RT. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101: 1328-1338, 2007.
63. Zhang H, Tao L, Jiao X, Gao E, Lopez BL, Christopher TA, Koch W, and Ma XL. Nitrative thioredoxin inactivation as a cause of enhanced myocardial ischemia/reperfusion injury in the aging heart. Free Radic Biol Med 43: 39-47, 2007.
64. Zschauer TC, Kunze K, Jakob S, Haendeler J, and Altschmied J. Oxidative stress-induced degradation of thioredoxin-1 and apoptosis is inhibited by thioredoxin-1-actin interaction in endothelial cells. Arterioscler Thromb Vasc Biol 31: 650-656, 2011.